Diseases of the Oropharynx
... A patient's voice also may have the classic muffled quality characteristic of severe tonsillar enlargement, but in lingual tonsillitis the uvula and peritonsillar area show no deviation or edema. ...
... A patient's voice also may have the classic muffled quality characteristic of severe tonsillar enlargement, but in lingual tonsillitis the uvula and peritonsillar area show no deviation or edema. ...
a comparison of two psychological
... purely verbal treatment and in most cases the improvements were sustained. This paper is concerned with a study which compared two different psychological treatments for bulimia nervosa. One of the treatments, the cognitive behavioural approach, was found in an earlier uncontrolled investigation to ...
... purely verbal treatment and in most cases the improvements were sustained. This paper is concerned with a study which compared two different psychological treatments for bulimia nervosa. One of the treatments, the cognitive behavioural approach, was found in an earlier uncontrolled investigation to ...
Cost-effectiveness analysis of the first-line therapies for
... month [23, 24]. These figures reflect the significant rate of relapse within the first several weeks of cessation therapy. We estimated the price of each treatment based on 2001 pharmacy list prices provided in the drug therapy book for Switzerland [25]. We based the costs associated with GPs’ time on a ...
... month [23, 24]. These figures reflect the significant rate of relapse within the first several weeks of cessation therapy. We estimated the price of each treatment based on 2001 pharmacy list prices provided in the drug therapy book for Switzerland [25]. We based the costs associated with GPs’ time on a ...
1 PRODUCT MONOGRAPH PENNSAID (1.5% w/w diclofenac
... was seen in 4 of 117 (3.4%) patients using PENNSAID, 6 of 111 (5.4%) using vehiclecontrol and 2 of 108 (1.9%) using placebo. In most cases the increase was minimal and in two patients (one treated with PENNSAID, one treated with vehicle-control) the increase was 2.5 times normal. ...
... was seen in 4 of 117 (3.4%) patients using PENNSAID, 6 of 111 (5.4%) using vehiclecontrol and 2 of 108 (1.9%) using placebo. In most cases the increase was minimal and in two patients (one treated with PENNSAID, one treated with vehicle-control) the increase was 2.5 times normal. ...
Diabetic Retinopathy and Diabetic Macular Edema
... reduced the risk of moderate visual loss (3 lines) by approximately 50%.12 Focal laser treatment may need to be repeated at 4-month intervals until a response or complete treatment is achieved. Recent Clinical Trial Results: Advancements in Therapy for DME Most recently, treatments other than laser ...
... reduced the risk of moderate visual loss (3 lines) by approximately 50%.12 Focal laser treatment may need to be repeated at 4-month intervals until a response or complete treatment is achieved. Recent Clinical Trial Results: Advancements in Therapy for DME Most recently, treatments other than laser ...
Considerations for Surgery - CARE-NMD
... conscious sedation or regional anaesthesia if the last investigation was more than one year previously, or if there has been an abnormal echocardiogram in the preceding 7-12 months. • For local anaesthesia, an echocardiogram should be performed if there had been an abnormal result obtained previousl ...
... conscious sedation or regional anaesthesia if the last investigation was more than one year previously, or if there has been an abnormal echocardiogram in the preceding 7-12 months. • For local anaesthesia, an echocardiogram should be performed if there had been an abnormal result obtained previousl ...
training module for community pharmacists
... Fig. 1. India is the largest TB burden country accounting for one-fifth of the global incidence One untreated case of pulmonary TB can infect 10 to 15 persons in one year. 2.4 HIV Co infection among TB patients In India, it is estimated that 2.31 million individuals are living with HIV infection, w ...
... Fig. 1. India is the largest TB burden country accounting for one-fifth of the global incidence One untreated case of pulmonary TB can infect 10 to 15 persons in one year. 2.4 HIV Co infection among TB patients In India, it is estimated that 2.31 million individuals are living with HIV infection, w ...
Emergency Management of the Acutely Poisoned Patient
... Maintain on 10mg/kg/d in 3dd x 6wks If Vit B1/B6 combination, do not give more than 1g of Vit B1 at any one bolus; repeat every 5 minutes until total required B6 is given ...
... Maintain on 10mg/kg/d in 3dd x 6wks If Vit B1/B6 combination, do not give more than 1g of Vit B1 at any one bolus; repeat every 5 minutes until total required B6 is given ...
the Kanuma Prescribing Information
... patients. In clinical trials, 3 of 106 (3%) patients treated with KANUMA experienced signs and symptoms consistent with anaphylaxis. These patients experienced reactions during infusion with signs and symptoms including chest discomfort, conjunctival injection, dyspnea, generalized and itchy rash, h ...
... patients. In clinical trials, 3 of 106 (3%) patients treated with KANUMA experienced signs and symptoms consistent with anaphylaxis. These patients experienced reactions during infusion with signs and symptoms including chest discomfort, conjunctival injection, dyspnea, generalized and itchy rash, h ...
Monoclonal antibodies in ophthalmology
... and human IgG1 base. It has been tried successfully in various pathological conditions of eye. It has been effectively used for managing the refractory uveoretinitis in Behçet's disease. There is significant reduction in inflammation, improvement of visual acuity, and decrease in ocular complication ...
... and human IgG1 base. It has been tried successfully in various pathological conditions of eye. It has been effectively used for managing the refractory uveoretinitis in Behçet's disease. There is significant reduction in inflammation, improvement of visual acuity, and decrease in ocular complication ...
Drug induced muscle disorders - ResearchOnline@JCU
... Myotoxic drugs. Numerous drugs cause myotoxic effects by various mechanisms making it unrealistic to discuss them all. Table 1 lists drugs that are known to be myotoxic in some individuals. The primary cause is direct toxicity and this is often (but not always) dose-related. Secondary causes include ...
... Myotoxic drugs. Numerous drugs cause myotoxic effects by various mechanisms making it unrealistic to discuss them all. Table 1 lists drugs that are known to be myotoxic in some individuals. The primary cause is direct toxicity and this is often (but not always) dose-related. Secondary causes include ...
LCD for Hospice - Determining Terminal Status
... applicable to all hospice patients. It is intended to be used to identify any Medicare beneficiary whose current clinical status and anticipated progression of disease is more likely than not to result in a life expectancy of six months or less. Clinical variables with general applicability without ...
... applicable to all hospice patients. It is intended to be used to identify any Medicare beneficiary whose current clinical status and anticipated progression of disease is more likely than not to result in a life expectancy of six months or less. Clinical variables with general applicability without ...
Risk factors and treatment outcomes in osteomyelitis Alan D. Tice
... Downloaded from http://jac.oxfordjournals.org/ by guest on September 9, 2014 ...
... Downloaded from http://jac.oxfordjournals.org/ by guest on September 9, 2014 ...
The effect of continuous ultrasound on chronic low back pain
... ultrasound plus exercise therapy or placebo ultrasound plus exercise therapy. These groups will be treated for 10 sessions during a period of 4 weeks. Primary outcome measures will be functional disability and pain intensity. Lumbar flexion and extension range of motion, as well as changes in electr ...
... ultrasound plus exercise therapy or placebo ultrasound plus exercise therapy. These groups will be treated for 10 sessions during a period of 4 weeks. Primary outcome measures will be functional disability and pain intensity. Lumbar flexion and extension range of motion, as well as changes in electr ...
Treatment of ptosis in chronic progressive external ophthalmoplegia
... influenced by the medical status of the patient and has an unpredictable outcome; patients with myasthenia gravis were therefore excluded from the study. Subjects and methods Seventeen patients with severe ptosis and CPEO presented to the Lid Clinic at Moorfields Eye Hospital over a period of six ye ...
... influenced by the medical status of the patient and has an unpredictable outcome; patients with myasthenia gravis were therefore excluded from the study. Subjects and methods Seventeen patients with severe ptosis and CPEO presented to the Lid Clinic at Moorfields Eye Hospital over a period of six ye ...
Drug therapy for ventricular tachyarrhythmias: How many
... antiarrhythmic drug therapy with long-term efficacy by the electropharmacologic approach for patients with inducible ventricular tachyarrhythmias is a function of the number of preceding unsuccessful trials. The probabilities of identifying therapy with long-term efficacy are highest for the first ( ...
... antiarrhythmic drug therapy with long-term efficacy by the electropharmacologic approach for patients with inducible ventricular tachyarrhythmias is a function of the number of preceding unsuccessful trials. The probabilities of identifying therapy with long-term efficacy are highest for the first ( ...
Neurological involvement in Primary Sjögren`s Syndrome
... was significantly higher (p< 0,05) and the articular symptoms were significantly less frequent (p< 0,05) in pSS with neurological involvement. The neurologic outcome was good in 77% of the patients. Conclusion: The current study underlines the diversity of neurologic complications of pSS. The freque ...
... was significantly higher (p< 0,05) and the articular symptoms were significantly less frequent (p< 0,05) in pSS with neurological involvement. The neurologic outcome was good in 77% of the patients. Conclusion: The current study underlines the diversity of neurologic complications of pSS. The freque ...
Skin test - WordPress.com
... not prevent “anaphylactic shock” ? If known to cause a previous reaction, avoid using that drug/agent. ...
... not prevent “anaphylactic shock” ? If known to cause a previous reaction, avoid using that drug/agent. ...
Acute Bacterial Skin and Skin Structure Infections: Review and Update
... Fusidic acid cream is also effective, however, it is not available in the U.S. A third topical agent, retapamulin (Altabax®), also carries an FDA-approved indication for children (nine months of age and older) and adults. This agent is the first member in a new class of antibacterial agents called p ...
... Fusidic acid cream is also effective, however, it is not available in the U.S. A third topical agent, retapamulin (Altabax®), also carries an FDA-approved indication for children (nine months of age and older) and adults. This agent is the first member in a new class of antibacterial agents called p ...
multiple sclerosis
... initiates inflammation. However, there is no conclusive proof that viruses are a direct cause of MS, and infection with and Epstein-Barr and other viruses probably contributes to a susceptibility to MS but is not a primary cause of the disease. Multiple sclerosis is not contagious. The environmental ...
... initiates inflammation. However, there is no conclusive proof that viruses are a direct cause of MS, and infection with and Epstein-Barr and other viruses probably contributes to a susceptibility to MS but is not a primary cause of the disease. Multiple sclerosis is not contagious. The environmental ...
Clinical Practice Guidelines for Physiotherapy Management of
... maintaining or restoring function that has been impaired by injury or disease. 6. Manual therapy means the skillful and trained use of the physical therapists’ hands to manipulate, mobilize, resist and/or move the human body to reduce pain, restore function, and promote healing. 7. Therapeutic exerc ...
... maintaining or restoring function that has been impaired by injury or disease. 6. Manual therapy means the skillful and trained use of the physical therapists’ hands to manipulate, mobilize, resist and/or move the human body to reduce pain, restore function, and promote healing. 7. Therapeutic exerc ...
immunomodulators and antiparasites
... damage to myelin Reduce inflammation by: – Switching cytokine production from type 1 (pro-inflammatory) to type 2 (anti-inflammatory) cells – Decrease antigen presentation, to reduce the attack on myelin ...
... damage to myelin Reduce inflammation by: – Switching cytokine production from type 1 (pro-inflammatory) to type 2 (anti-inflammatory) cells – Decrease antigen presentation, to reduce the attack on myelin ...
Lyme disease: A Look Beyond Antibiotics
... hormone that made our patients ill. We discovered that toxicity and chronic infections were most often at the core of the client’s suffering. We watched the discussion, which infection may be the primary one: mycoplasma, stealth viruses, HHV-6, trichomonas, Chlamydia pneumoniae, leptospirosis, mutat ...
... hormone that made our patients ill. We discovered that toxicity and chronic infections were most often at the core of the client’s suffering. We watched the discussion, which infection may be the primary one: mycoplasma, stealth viruses, HHV-6, trichomonas, Chlamydia pneumoniae, leptospirosis, mutat ...
The follow-up results with sustained virologic response in chronic
... and degree of fibrosis. In addition, other important predictive factors include host factors such as basal HCV RNA levels, dose and duration of treatment, body mass index (BMI), age, insulin resistance, gender, liver enzyme levels, including ALT and GGT, and co-infection with HIV or other hepatotrop ...
... and degree of fibrosis. In addition, other important predictive factors include host factors such as basal HCV RNA levels, dose and duration of treatment, body mass index (BMI), age, insulin resistance, gender, liver enzyme levels, including ALT and GGT, and co-infection with HIV or other hepatotrop ...
Dave Cook, Blueberry Therapeutics
... Oncology treatment value model based on frameworks like QALY (Quality Adjusted Life Years) Our product vision: tailored treatments curing patients of a life-threatening infection and returning them to many years of productive, high-quality life Blueberry Therapeutics ...
... Oncology treatment value model based on frameworks like QALY (Quality Adjusted Life Years) Our product vision: tailored treatments curing patients of a life-threatening infection and returning them to many years of productive, high-quality life Blueberry Therapeutics ...
Management of multiple sclerosis
Several therapies for multiple sclerosis (MS) exist, although there is no known cure. Multiple sclerosis is a chronic inflammatory demyelinating disease that affects the central nervous system (CNS).The most common initial course of the disease is the relapsing-remitting subtype, which is characterized by unpredictable attacks (relapses) followed by periods of relative remission with no new signs of disease activity. After some years, many of the people who have this subtype begin to experience neurologic decline without acute relapses. When this happens it is called secondary progressive multiple sclerosis. Other, less common, courses of the disease are the primary progressive (decline from the beginning without attacks) and the progressive-relapsing (steady neurologic decline and superimposed attacks). Different therapies are used for patients experiencing acute attacks, for patients who have the relapsing-remitting subtype, for patients who have the progressive subtypes, for patients without a diagnosis of MS who have a demyelinating event, and for managing the various consequences of MS.The primary aims of therapy are returning function after an attack, preventing new attacks, and preventing disability. As with any medical treatment, medications used in the management of MS may have several adverse effects, and many possible therapies are still under investigation. At the same time different alternative treatments are pursued by many patients, despite the paucity of supporting, comparable, replicated scientific study.This article focuses on therapies for standard MS; borderline forms of MS have particular treatments that are excluded.